Singapore markets open in 32 minutes

Novo Nordisk A/S (NVO)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
126.16-2.48 (-1.93%)
At close: 04:00PM EDT
124.89 -1.27 (-1.01%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close128.64
Open127.16
Bid125.50 x 1200
Ask125.70 x 1000
Day's range125.35 - 127.32
52-week range75.56 - 138.28
Volume3,007,254
Avg. volume5,036,312
Market cap562.841B
Beta (5Y monthly)0.19
PE ratio (TTM)47.43
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield1.37 (1.07%)
Ex-dividend date22 Mar 2024
1y target estN/A
All
News
  • GlobeNewswire

    Novo Nordisk A/S – Reduction of the share capital

    Bagsværd, Denmark, 24 April 2024 – At Novo Nordisk’s Annual General Meeting on 21 March 2024, it was decided to reduce the company’s B share capital from DKK 343,512,800 to DKK 339,012,800 by cancellation of part of the company’s portfolio of own B shares equal to a nominal value of DKK 4,500,000 divided into 45,000,000 B shares of DKK 0.10 each. Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B shares a

  • GlobeNewswire

    Novo Nordisk A/S - share repurchase programme

    Bagsværd, Denmark, 22 April 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the programme i

  • GlobeNewswire

    Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

    Bagsværd, Denmark, 15 April 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by t